Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9145
Full metadata record
DC FieldValueLanguage
dc.contributor.authorChu, Wen-Kai-
dc.contributor.authorWu, Un-In-
dc.contributor.authorLee, Tai-Fen-
dc.contributor.authorCheng, Aristine-
dc.contributor.authorChen, Kai-Hsiang-
dc.contributor.authorLin, Kuan-Yin-
dc.date.accessioned2024-12-17T03:00:27Z-
dc.date.available2024-12-17T03:00:27Z-
dc.date.issued2023-02-
dc.identifier.citationShort Communicationen_US
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9145-
dc.description.abstractis. Newer azoles are alternatives for patients refractory to or intolerant of standard therapy. We report an 83-year-old woman with rheumatoid arthritis complicated with pleuropulmonary histoplasmosis who responded to liposomal amphotericin B, but progressed under voriconazole and posaconazole maintenance therapy.en_US
dc.language.isoen_USen_US
dc.publisherJournal of Microbiologi, Immunology and Infectionen_US
dc.subjectHistoplasma capsulatumen_US
dc.subjectRheumatoid arthritisen_US
dc.subjectSalvage treatmenten_US
dc.subjectVoriconazoleen_US
dc.subjectPosaconazoleen_US
dc.subjectNon-endemic areaen_US
dc.titleA difficult-to-treat pleuropulmonary histoplasmosis in a patient with rheumatoid arthritis in Taiwanen_US
dc.typeArticleen_US
Appears in Collections:VOL 56 NO 1 2023

Files in This Item:
File Description SizeFormat 
192-196.pdf548.88 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.